98%
921
2 minutes
20
Background: The neutrophil percentage-to-albumin ratio (NPAR) has emerged as a widely used inflammatory marker for predicting clinical outcomes across various diseases; however, its prognostic value in hypercapnic respiratory failure (HRF) remains uncertain. This study aimed to examine the association between NPAR and all-cause mortality in patients with HRF.
Methods: This prospective cohort study enrolled 561 HRF patients hospitalized at Yancheng First People's Hospital between October 2020 and September 2021. The primary outcome was 24-month all-cause mortality; secondary outcomes included mortality at 3, 6, and 12 months. The association between NPAR and all-cause mortality was assessed using restricted cubic spline (RCS) modeling, multivariate Cox proportional hazards models, Kaplan-Meier survival analysis, and subgroup analyses. Discriminatory performance was evaluated using the area under the receiver operating characteristic curve (AUC).
Results: RCS modeling demonstrated a significant linear association between NPAR and all-cause mortality in HRF patients (P for overall association < 0.001). Both the Cox models and Kaplan-Meier analyses indicated that elevated NPAR levels were significantly associated with increased 3-, 6-, 12-, and 24-month all-cause mortality (all P < 0.05). Subgroup analysis further supported an independent association between NPAR and mortality. The AUC for NPAR in predicting 12-month all-cause mortality was 0.66 (95% confidence interval [CI], 0.61-0.71), which was significantly higher than that of neutrophil percentage or albumin alone (AUC =0.62; 95% CI, 0.57-0.67; P < 0.05).
Conclusion: Elevated NPAR is independently associated with increased all-cause mortality in patients with HRF. As a composite marker reflecting both systemic inflammation and nutritional status, NPAR may serve as a robust prognostic indicator to enhance risk stratification and guide clinical decision-making in HRF management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357578 | PMC |
http://dx.doi.org/10.2147/IJGM.S520510 | DOI Listing |
Ren Fail
December 2025
Department of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, China.
Purpose: This study aimed to investigate the association between body roundness index (BRI) and deaths from all causes and cardiovascular disease (CVD) in participants with chronic kidney disease (CKD).
Materials And Methods: The data was sourced from the National Health and Nutrition Examination Survey (NHANES) 1999-2018. Cox proportional hazards regression along with restricted cubic splines were applied to assess the associations of BRI with deaths from all causes and CVD in individuals with CKD.
Ren Fail
December 2025
Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
The Grams model, designed to predict adverse event risks in advanced chronic kidney disease (CKD) patients, was evaluated in a Chinese cohort of 1,333 patients with eGFR below 30 mL/min/1.73 m. The model demonstrated moderate to good discrimination across outcomes, performing well in predicting kidney replacement therapy (KRT) but overestimating the risks of cardiovascular disease (CVD) and mortality.
View Article and Find Full Text PDFEur J Clin Pharmacol
September 2025
Department of Forensic Pathology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, China.
Background And Objective: While current clinical guidelines generally advocate for beta-blocker therapy following acute myocardial infarction (AMI), conflicting findings have surfaced through large-scale observational studies and meta-analyses. We conducted this systematic review and meta-analysis of published observational studies to quantify the long-term therapeutic impact of beta-blocker across heterogeneous AMI populations.
Methods: We conducted comprehensive searches of the PubMed, Embase, Cochrane, and Web of Science databases for articles published from 2000 to 2025 that examine the link between beta-blocker therapy and clinical outcomes (last search update: March 1, 2025).
Cardiovasc Revasc Med
September 2025
Division of Vascular Surgery, Cardiovascular Center, Tufts Medical Center, Boston, MA, USA; Tufts University School of Medicine, Boston, MA, USA. Electronic address:
Background: protamine sulfate is used to reduce bleeding risk after Carotid Artery Stenting (CAS), but its efficacy in personalized patient settings remains underexplored. This study aims to identify factors associated with greater benefits from protamine sulfate following CAS.
Methods: A retrospective review of Vascular Quality Initiative (VQI) data (2016-2022) identified patients undergoing CAS, divided into Transfemoral CAS (TF-CAS) and Transcarotid artery revascularization (TCAR) groups.
Acad Radiol
September 2025
Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan (J.Y.H., C.L.K., K.L.C.); College of Medicine, National Taiwan University, Taipei, Taiwan (J.Y.H., C.K.H., K.L.C., Y.W.W.); Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan (C.K
Rationale And Objectives: The prognostic implications of myocardial perfusion imaging (MPI) are imperative to provide proper management of coronary artery disease (CAD). This study aimed to quantify the long-term prognostic value of MPI under routine clinical conditions.
Materials And Methods: This single-center retrospective cohort study evaluated all-cause mortality and cause-specific survival according to MPI findings in patients with suspected or known CAD who underwent diagnostic evaluation or assessment of myocardial ischemia and viability in a tertiary referral cardiovascular center.